KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Deferred Taxes (2018 - 2020)

Ionis Pharmaceuticals has reported Deferred Taxes over the past 3 years, most recently at $340.1 million for Q4 2020.

  • Quarterly results put Deferred Taxes at $340.1 million for Q4 2020, up 10754.14% from a year ago — trailing twelve months through Sep 2021 was $340.1 million (up 22140.18% YoY), and the annual figure for FY2020 was $341.7 million, up 37411.42%.
  • Deferred Taxes for Q4 2020 was $340.1 million at Ionis Pharmaceuticals, up from $1.5 million in the prior quarter.
  • Over the last five years, Deferred Taxes for IONS hit a ceiling of $340.1 million in Q4 2020 and a floor of -$290.5 million in Q4 2018.
  • Median Deferred Taxes over the past 3 years was $887000.0 (2019), compared with a mean of $5.8 million.
  • Peak annual rise in Deferred Taxes hit 10754.14% in 2020, while the deepest fall reached 116.89% in 2020.
  • Ionis Pharmaceuticals' Deferred Taxes stood at -$290.5 million in 2018, then soared by 98.9% to -$3.2 million in 2019, then soared by 10754.14% to $340.1 million in 2020.
  • The last three reported values for Deferred Taxes were $340.1 million (Q4 2020), $1.5 million (Q3 2020), and $2.5 million (Q2 2020) per Business Quant data.